Filing Flows › Comparisons › RNXT vs USAQ
RenovoRx vs QHSLab: RNXT and USAQ compared
RenovoRx is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $847K for QHSLab (Q2 2026). RenovoRx is growing faster (+301% against +40% a year earlier). QHSLab is more profitable, with an operating margin of 5.3% against -303.6%.
Where the money goes: RNXT and USAQ
RenovoRx (RNXT) · Q3 2026
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
QHSLab (USAQ) · Q2 2026
QHSLab, Q2 2026: revenue $847K (+40% year over year), operating margin 5.3%, net earnings $38K, operating cash flow −$8K. The chart follows the revenue to costs, profit and cash.
| RenovoRx (RNXT) | QHSLab (USAQ) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $1.1M | $847K |
| Revenue growth, Y/Y | +301% | +40% |
| Gross margin | — | 69.6% |
| Operating margin | -303.6% | 5.3% |
| Net earnings | −$3.6M | $38K |
| Net margin | -342.1% | 4.5% |
| Operating cash flow | −$2.5M | −$8K |
Where the revenue comes from
QHSLab
- Integrated Service Program: $491K (58%)
- Allergy Diagnostic Kit Sales: $196K (23%)
- Immunotherapy Treatment Sales: $94K (11%)
- Clinical Study Revenue: $30K (4%)
Questions
Which is bigger, RenovoRx or QHSLab?
RenovoRx is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $847K for QHSLab (Q2 2026).
Is RenovoRx or QHSLab growing faster?
RenovoRx is growing faster (+301% against +40% a year earlier).
Which is more profitable, RenovoRx or QHSLab?
QHSLab is more profitable, with an operating margin of 5.3% against -303.6%.
More: RenovoRx earnings · how RenovoRx makes money · QHSLab earnings · how QHSLab makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.